Clinical Research Directory

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spectrum Disorder, relapsing Myelin Oligodendrocyte Glycoprotein Antiody-Associated Disease, refractory AutoImmune Encephalitis, and refractory Stiff Person Syndrome

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.

A Basket Study of CTA313 in Participants With Active Autoimmune Diseases

The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders. Participants with SLE, pMS and AIE between the ages of 18 and 75 will be eligible to participate. Participants will receive one infusion of CTA313 on Day 0. During the Dose Confirmation portion, cohorts will be independently evaluated for safety and to establish the RP2D of CTA313. During the Cohort Expansion portion of the study patients will be evaluated to further confirm the efficacy and safety of CTA313. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis

The Effects of a 12-week In-phase Bilateral Exercise Programme on the Corticospinal Plasticity in People With Progressive Multiple Sclerosis

This study investigates whether a structured exercise program using coordinated movements of both arms can improve brain and motor function in people with Progressive Multiple Sclerosis (MS). Progressive MS is associated with gradual worsening of neurological function, including difficulties with movement, strength, balance, and cognition. Because current medications have limited effects on disease progression, rehabilitation strategies that promote brain plasticity and functional recovery are increasingly important. In this study, five individuals with Progressive Multiple Sclerosis participated in a 12-week exercise program consisting of in-phase bilateral upper-limb movements performed three times per week. Brain activity related to movement was measured using transcranial magnetic stimulation (TMS), which assessed corticospinal excitability through active motor threshold measurements. Additional clinical tests evaluated walking speed, balance, hand dexterity, muscle strength, cognitive processing speed, fatigue, and quality of life. The study used a single-case experimental design with repeated measurements during baseline and intervention phases to determine whether the exercise program produced measurable neurophysiological and functional changes.